Zobrazeno 1 - 10
of 205
pro vyhledávání: '"Stephen E. Langabeer"'
Autor:
Stephen E. Langabeer
Publikováno v:
EXCLI Journal : Experimental and Clinical Sciences, Vol 22, Pp 67-69 (2023)
Externí odkaz:
https://doaj.org/article/83f30bef1ef540f9842097fa82f5c562
Publikováno v:
Technology in Cancer Research & Treatment, Vol 22 (2023)
Externí odkaz:
https://doaj.org/article/9c36a62079974d84bd46daf0b2e64cb5
Autor:
Stephen E. Langabeer
Publikováno v:
Journal of Kidney Cancer and VHL, Vol 10, Iss 1 (2023)
N/A
Externí odkaz:
https://doaj.org/article/946e8f4548684887b5b4169d97211782
Publikováno v:
Case Reports in Hematology, Vol 2023 (2023)
Acquired resistance to tyrosine kinase inhibitors (TKIs) remains a therapeutic challenge in the treatment of chronic myeloid leukemia (CML). The most studied reason for TKI resistance is the acquisition of mutations within the BCR::ABL1 tyrosine kina
Externí odkaz:
https://doaj.org/article/45cfd3120dc54aeb8d83cad8344691e7
Absence of JAK2 V617F-mutated polycythemia vera in obstructive sleep apnea-associated erythrocytosis
Autor:
Stephen E. Langabeer
Publikováno v:
Sleep Medicine: X, Vol 4, Iss , Pp 100058- (2022)
Externí odkaz:
https://doaj.org/article/f682c3b811cf41b485d7bb3c0c045c7d
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 44, Iss 1, Pp 130-131 (2022)
Externí odkaz:
https://doaj.org/article/f2ce335f13c346a497099ec2247b180e
Publikováno v:
TH Open, Vol 05, Iss 02, Pp e174-e175 (2021)
Externí odkaz:
https://doaj.org/article/b2d0dca35d5d41cf95b511c46b6d69b7
Autor:
Stephen E. Langabeer
Publikováno v:
EXCLI Journal : Experimental and Clinical Sciences, Vol 20, Pp 1608-1609 (2021)
Externí odkaz:
https://doaj.org/article/9febee98177442fab5442f5c6c627f0b
Autor:
Stephen E. Langabeer
Publikováno v:
Leukemia Research Reports, Vol 14, Iss , Pp 100218- (2020)
Externí odkaz:
https://doaj.org/article/3094df1262e34d5ea61d5fb69d677617
Publikováno v:
Case Reports in Hematology, Vol 2020 (2020)
The introduction of tyrosine kinase inhibitors (TKI) has revolutionised the management of patients with chronic myeloid leukemia (CML) over the last twenty years, but despite significant improvements in survival, patients exhibit long-term side effec
Externí odkaz:
https://doaj.org/article/02131a6808784dd695dee22c542ef7ad